Antiphospholipid Antibody Syndrome and its Effect on Hepatobiliary Health in Outpatient Population
Category: Early Detection & Risk Prediction
Conference Year: 2020
Antiphospholipid syndrome (APS) is an autoimmune disease characterized by the presence of abnormal immune proteins in the blood leading to involvement of multiple organs. Main focus of research in APS have been on heart, lungs and brain. It can cause many health problems, such as heart attack, pulmonary embolism, stroke, kidney damage, and deep vein thrombosis. To our knowledge, few studies have addressed the effect of the antiphospholipid syndrome on the liver function. The presence of M2antibodies is associated with Primary Biliary Cholangitis (PBC) and later development of Hepatococellular cancer. We explored the association of M2antibodies with antiphospholipid antibody titers. Patients examined by physicians at clinics in Texas from 5 May 2018 - 17 May 2019 were included in the study to analyze the association between antiphospholipid antibodies and M2antibodies. Demographic, and laboratory information were obtained from medical records. Logistic regression models were employed to determine association between presence of M2antibodies and the presence of different antiphospholipid antibodies. Four different categories of antiphospholipid antibodies (aPAs); antibodies against Beta-2-Glycoprotein-1, Cardiolipin, Phosphatidylserine and Phosphatidylserine/Prothrombin complex (aPS/PT) and silica clotting time and DRVVT were analyzed. Five thousand six hundred and fifty-six patients (mean age 55 years; range 19-98) with a predominant proportion of females (54%) were examined at clinics during the study period. Three percent of patients (163/5,656) had a positive test for M2antibodies. Using multivariable logistic regression, after controlling for age, gender and ethnicity we calculated odds ratios (ORs) and 95% confidence intervals (CIs) for associations of M2-antibodies with ApL antibodies. Analysis showed that M2-antibodies in the body are statistically associated with presence of AntiCardiolipinIgG (5.67; 95%CI 2.02:15.94) P<0.01), AntiCardiolipinIgM (2.79; 95%CI 1.17.3; P<0.05), AntiPhosphatidylserineIgM (2.61; 95%CI 1.17:5.84; P<0.02). Association of aPL with M2antibodies indicates that chronic immuno‐inflammatory state of liver can cause hepatobiliary cancers in patients with APS. Patients with APS should be screened for hepatobiliary cancer.
Keywords: M2antibodies, Antiphospholipid antibodies